ATE187648T1 - Zusammensetzungen enthaltend lipoprotein- associated-coagulation-inhibitor (laci) zur herstellung eines medikaments zur behandlung von akuten oder chronischen enzündungen - Google Patents

Zusammensetzungen enthaltend lipoprotein- associated-coagulation-inhibitor (laci) zur herstellung eines medikaments zur behandlung von akuten oder chronischen enzündungen

Info

Publication number: ATE187648T1
Authority: AT; Austria
Prior art keywords: laci; treatment; medication; acute; producing
Prior art date: 1992-06-01

Application number

AT93910775T

Other languages

English (en)

Inventor

Abla A Creasey

Original Assignee

Chiron Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-06-01

Filing date

1993-04-23

Publication date

2000-01-15

1993-04-23 Application filed by Chiron Corp filed Critical Chiron Corp

2000-01-15 Application granted granted Critical

2000-01-15 Publication of ATE187648T1 publication Critical patent/ATE187648T1/de

Links

102100030951 Tissue factor pathway inhibitor Human genes 0.000 title abstract 5
108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 title abstract 3
208000038016 acute inflammation Diseases 0.000 title 1
230000006022 acute inflammation Effects 0.000 title 1
208000037976 chronic inflammation Diseases 0.000 title 1
230000006020 chronic inflammation Effects 0.000 title 1
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
239000000203 mixture Substances 0.000 title 1
239000003112 inhibitor Substances 0.000 abstract 3
206010061218 Inflammation Diseases 0.000 abstract 2
206010040047 Sepsis Diseases 0.000 abstract 2
206010040070 Septic Shock Diseases 0.000 abstract 2
101710139626 Tissue factor pathway inhibitor Proteins 0.000 abstract 2
230000004054 inflammatory process Effects 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
230000036303 septic shock Effects 0.000 abstract 2
102000002262 Thromboplastin Human genes 0.000 abstract 1
108010000499 Thromboplastin Proteins 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Oncology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

AT93910775T 1992-06-01 1993-04-23 Zusammensetzungen enthaltend lipoprotein- associated-coagulation-inhibitor (laci) zur herstellung eines medikaments zur behandlung von akuten oder chronischen enzündungen ATE187648T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US89194792A	1992-06-01	1992-06-01
US450593A	1993-01-13	1993-01-13
PCT/US1993/003860 WO1993024143A1 (en)	1992-06-01	1993-04-23	A method for using lipoprotein associated coagulation inhibitor to treat sepsis

Publications (1)

Publication Number	Publication Date
ATE187648T1 true ATE187648T1 (de)	2000-01-15

Family

ID=26673093

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93910775T ATE187648T1 (de)	1992-06-01	1993-04-23	Zusammensetzungen enthaltend lipoprotein- associated-coagulation-inhibitor (laci) zur herstellung eines medikaments zur behandlung von akuten oder chronischen enzündungen

Country Status (10)

Country	Link
EP (1)	EP0643585B1 (de)
JP (3)	JP3957740B2 (de)
AT (1)	ATE187648T1 (de)
CA (1)	CA2136953C (de)
DE (1)	DE69327314T2 (de)
DK (1)	DK0643585T3 (de)
ES (1)	ES2139658T3 (de)
GR (1)	GR3032779T3 (de)
PT (1)	PT643585E (de)
WO (1)	WO1993024143A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5824644A (en) *	1994-07-07	1998-10-20	G. D. Searle & Co.	Method of attenuating arterial stenosis
US5648331A (en) *	1994-08-26	1997-07-15	G.D. Searle & Co.	Method of inhibiting tissue ischemia and reperfusion injury
US5914316A (en) *	1994-12-16	1999-06-22	Washington University	Method of inhibiting intimal hyperplasia
WO1996040224A1 (en) *	1995-06-07	1996-12-19	Chiron Corporation	Regulation of cytokine synthesis and release
US5772629A (en) *	1995-10-23	1998-06-30	Localmed, Inc.	Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels
US5981471A (en) *	1997-02-06	1999-11-09	Entremed, Inc.	Compositions and methods for inhibiting cellular proliferation
CA2360347C (en)	1998-12-31	2013-05-07	Chiron Corporation	Improved expression of hiv polypeptides and production of virus-like particles
AU2002228911A1 (en) *	2000-11-08	2002-05-21	The General Hospital Corporation	Methods for inhibiting pain
US6939716B2 (en)	2001-09-19	2005-09-06	Washington University	Method for detecting conditions indicative of sepsis
CA2463655A1 (en) *	2001-10-15	2003-04-24	Chiron Corporation	Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
EP1654283B1 (de)	2003-08-13	2011-07-13	Novartis Vaccines and Diagnostics, Inc.	Verbessertes verfahren zur reinigung von tfpi und tfpi-analogen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK408089D0 (da) *	1989-08-18	1989-08-18	Novo Nordisk As	Proteiner

1993
- 1993-04-23 WO PCT/US1993/003860 patent/WO1993024143A1/en not_active Ceased
- 1993-04-23 ES ES93910775T patent/ES2139658T3/es not_active Expired - Lifetime
- 1993-04-23 CA CA002136953A patent/CA2136953C/en not_active Expired - Fee Related
- 1993-04-23 EP EP93910775A patent/EP0643585B1/de not_active Expired - Lifetime
- 1993-04-23 DE DE69327314T patent/DE69327314T2/de not_active Expired - Fee Related
- 1993-04-23 PT PT93910775T patent/PT643585E/pt unknown
- 1993-04-23 DK DK93910775T patent/DK0643585T3/da active
- 1993-04-23 JP JP50053094A patent/JP3957740B2/ja not_active Expired - Fee Related
- 1993-04-23 AT AT93910775T patent/ATE187648T1/de not_active IP Right Cessation
2000
- 2000-02-28 GR GR20000400481T patent/GR3032779T3/el not_active IP Right Cessation
2004
- 2004-04-20 JP JP2004124804A patent/JP2004210801A/ja not_active Withdrawn
2007
- 2007-03-02 JP JP2007053543A patent/JP2007137901A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP2004210801A (ja)	2004-07-29
GR3032779T3 (en)	2000-06-30
EP0643585B1 (de)	1999-12-15
CA2136953A1 (en)	1993-12-09
DE69327314T2 (de)	2000-04-13
PT643585E (pt)	2000-05-31
WO1993024143A1 (en)	1993-12-09
JP3957740B2 (ja)	2007-08-15
DK0643585T3 (da)	2000-05-08
CA2136953C (en)	2006-10-31
ES2139658T3 (es)	2000-02-16
EP0643585A1 (de)	1995-03-22
JPH07507300A (ja)	1995-08-10
JP2007137901A (ja)	2007-06-07
DE69327314D1 (de)	2000-01-20

Similar Documents

Publication	Publication Date	Title
DE68919358D1 (de)	1994-12-15	Zusammensetzung zur behandlung der schizophrenie.
DE69027865D1 (de)	1996-08-22	ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
DE69132688D1 (de)	2001-09-20	Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE69218255D1 (de)	1997-04-17	Verwendung von amino-2-trifluormethoxy-6-benzothiazol (riluzol) zur herstellung eines medikamentes zur behandlung von erkrankungen des motoneurons
ATE157542T1 (de)	1997-09-15	Verwendung von einer disaccharidpolysulfat- aluminium verbindung zur herstellung eines medikaments zur behandlung von hämorrhoiden und zur wundheilung
DE69006684D1 (de)	1994-03-24	Verwendung einer Zusammensetzung zur Herstellung eines Arzneimittels zur Behandlung der Symptome der Unenthaltsamkeit.
DE69535264D1 (de)	2006-11-23	Verfahren zur behandlung von diabetes mittels kgf
ATE187648T1 (de)	2000-01-15	Zusammensetzungen enthaltend lipoprotein- associated-coagulation-inhibitor (laci) zur herstellung eines medikaments zur behandlung von akuten oder chronischen enzündungen
EA199800690A1 (ru)	1999-02-25	Замещенные n-[(аминоиминометил)фенилалкил]азагетероцикламиды сульфоновых кислот
AU5051693A (en)	1994-01-13	Method and composition for treating inflammatory bowel disorders
PT93935A (pt)	1991-02-08	Processo para a preparacao de uma composicao farmaceutica para o tratamento topico de acne vulgar contendo cetoconazol
ATE201597T1 (de)	2001-06-15	Verabreichung von riluzol zur behandlung von neuro-aids
ES2107470T3 (es)	1997-12-01	Producto que contiene factor de crecimiento y glutamina y uso del factor de crecimiento para el tratamiento de la mucosa intestinal.
DE59902666D1 (de)	2002-10-17	Edelfosin zur behandlung von hirntumoren
ATE169226T1 (de)	1998-08-15	Verwendung von aus blutplättchen gewonnenem wachstumsfaktor zur herstellung eines medikaments zur behandlung von gastrointestinaler geschwüre
DE69026511D1 (de)	1996-05-15	Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis
ATE430578T1 (de)	2009-05-15	Faktor viii oder von willebrand faktor zur behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen
ATE249832T1 (de)	2003-10-15	Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardation
ATE234613T1 (de)	2003-04-15	Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
DE69307702D1 (de)	1997-03-06	Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
DE59504374D1 (de)	1999-01-14	Verwendung von Deoxyspergualin zur Herstellung eines Arzneimittels zur Behandlung von entzündlich-hyperreaktiven Erkrankungen
DE69004267D1 (de)	1993-12-02	Glycyl-p-amino-pyridin zur behandlung von seniler demenz.
RU97109107A (ru)	1999-05-10	Способ лечения гнойных ран
SU1113093A1 (ru)	1984-09-15	Способ лечени остеомиелита
ATE201993T1 (de)	2001-06-15	Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie

Legal Events

Date	Code	Title	Description
2000-06-15	UEP	Publication of translation of european patent specification
2011-01-15	REN	Ceased due to non-payment of the annual fee